Viveve Medical (VIVE) 10-Q 13 May 21 2021 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2021	May 12, 2021
Document Information [Line Items]
Entity Registrant Name	VIVEVE MEDICAL, INC.
Entity Central Index Key	0000879682
Trading Symbol	vive
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		10,591,716
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Common Stock

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 28,446,000	$ 6,523,000	[1]
Accounts receivable, net of allowance for doubtful accounts of $126 and $124 as of March 31, 2021 and December 31, 2020, respectively	336,000	770,000	[1]
Inventory	3,049,000	3,254,000	[1]
Prepaid expenses and other current assets	2,043,000	2,296,000	[1]
Total current assets	33,874,000	12,843,000	[1]
Property and equipment, net	2,316,000	2,759,000	[1]
Investment in limited liability company	757,000	833,000	[1]
Other assets	723,000	195,000	[1]
Total assets	37,670,000	16,630,000	[1]
Current liabilities:
Accounts payable	1,157,000	881,000	[1]
Accrued liabilities	1,873,000	2,416,000	[1]
Paycheck Protection Program loan, current portion	1,246,000	918,000	[1]
Total current liabilities	4,276,000	4,215,000	[1]
Note payable, noncurrent portion	4,660,000	4,518,000	[1]
Paycheck Protection Program loan, noncurrent portion	97,000	425,000	[1]
Other noncurrent liabilities	1,097,000	498,000	[1]
Total liabilities	10,130,000	9,656,000	[1]
Commitments and contingences (Note 9)
Stockholders’ equity:
Common stock, $0.0001 par value; 75,000,000 shares authorized as of March 31, 2021 and December 31, 2020; 10,341,716 and 2,171,316 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively	1,000		[1]
Additional paid-in capital	253,156,000	226,800,000	[1]
Accumulated deficit	(225,617,000)	(219,826,000)	[1]
Total stockholders’ equity	27,540,000	6,974,000	[1]
Total liabilities and stockholders’ equity	37,670,000	16,630,000	[1]
Series B Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock			[1]
Series C Preferred Stock [Member]
Stockholders’ equity:
Convertible preferred stock			[1]
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020	[1]
Accounts receivable, allowance for doubtful accounts	$ 126	$ 124
Convertible preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	10,341,716	2,171,316
Common stock, shares outstanding (in shares)	10,341,716	2,171,316
Series B Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	36,937	35,819
Convertible preferred stock, shares outstanding (in shares)	36,937	35,819
Series C Preferred Stock [Member]
Convertible preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Convertible preferred stock, shares issued (in shares)	0
Convertible preferred stock, shares outstanding (in shares)	0
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 1,450	$ 1,304
Cost of revenue	1,068	1,129
Gross profit	382	175
Operating expenses:
Research and development	1,930	1,637
Selling, general and administrative	3,581	4,365
Total operating expenses	5,511	6,002
Loss from operations	(5,129)	(5,827)
Modification of warrants	(287)
Interest expense, net	(234)	(210)
Other expense, net	(65)	(91)
Net loss from consolidated companies	(5,715)	(6,128)
Loss from minority interest in limited liability company	(76)	(182)
Comprehensive and net loss	(5,791)	(6,310)
Series B convertible preferred stock dividends	(1,119)	(989)
Net loss attributable to common stockholders	$ (6,910)	$ (7,299)
Net loss per share of common stock:
Basic and diluted (in dollars per share)	$ (0.80)	$ (8.17)
Weighted average shares used in computing net loss per common share:
Basic and diluted (in shares)	8,636,120	893,079

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	January 2021 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	January 2021 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	January 2021 Offering [Member]Common Stock [Member]	January 2021 Offering [Member]Additional Paid-in Capital [Member]	January 2021 Offering [Member]Retained Earnings [Member]	January 2021 Offering [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	November 2019 Offering [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	November 2019 Offering [Member]Common Stock [Member]	November 2019 Offering [Member]Additional Paid-in Capital [Member]	November 2019 Offering [Member]Retained Earnings [Member]	November 2019 Offering [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Purchase Agreement with LPC [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Purchase Agreement with LPC [Member]Common Stock [Member]	Purchase Agreement with LPC [Member]Additional Paid-in Capital [Member]	Purchase Agreement with LPC [Member]Retained Earnings [Member]	Purchase Agreement with LPC [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Common Stock [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]Retained Earnings [Member]	Conversion of Series C Convertible Preferred Stock Into Common Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series A Preferred Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Preferred Stock [Member]Series B Preferred Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Common Stock [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Additional Paid-in Capital [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]Retained Earnings [Member]	Conversion of Series A Convertible Preferred Stock into Common Stock [Member]	Preferred Stock [Member]Series A Preferred Stock [Member]	Preferred Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Series B Preferred Stock [Member]	Total
Balances (in shares) at Dec. 31, 2019																															185,218	31,678	707,571
Balances at Dec. 31, 2019																																		$ 214,431	$ (197,911)		$ 16,521
Conversion of convertible preferred stock into common stock (in shares)																									(185,218)		185,218
Conversion of convertible preferred stock into common stock
Issuance of common shares in connection with common warrant exercises (in shares)																																	107,172
Issuance of common shares in connection with common warrant exercises																																		1,661			1,661
Transaction costs in connection with Purchase Agreement with LPC										$ (30)		$ (30)
Dividend on Series B convertible preferred stock																																		(990)			(990)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)																																989				989
Dividend on Series B convertible preferred stock paid in PIK shares																																		989			989
Stock-based compensation expense																																		686			686
Net loss																																			(6,310)		(6,310)
Issuance of common shares from employee stock purchase plan
Issuance of restricted common shares in connection with consulting agreement (in shares)																																	2,832
Issuance of restricted common shares in connection with consulting agreement																																		24			24
Balances (in shares) at Mar. 31, 2020																																32,667	1,002,793
Balances at Mar. 31, 2020																																		216,771	(204,221)		12,551
Balances (in shares) at Dec. 31, 2020																																35,819	2,171,316
Balances at Dec. 31, 2020																																		226,800	(219,826)		6,974	[1]
Stock offering, net of issuance costs (in shares)			5,666,760
Stock offering, net of issuance costs			$ 1	$ 25,121		$ 25,122
Conversion of convertible preferred stock into common stock (in shares)																					2,450,880
Conversion of convertible preferred stock into common stock
Issuance of common shares in connection with common warrant exercises (in shares)																																	52,760
Issuance of common shares in connection with common warrant exercises																																		179			179
Modification of exercise price of warrants in connection with January 2021 Offering																																		287			287
Transaction costs in connection with Purchase Agreement with LPC																$ (40)		$ (40)
Dividend on Series B convertible preferred stock																																		(1,119)			(1,119)
Dividend on Series B convertible preferred stock paid in PIK shares (in shares)																																1,118				1,118
Dividend on Series B convertible preferred stock paid in PIK shares																																		1,118			1,118
Stock-based compensation expense																																		810			810
Net loss																																			(5,791)		(5,791)
Balances (in shares) at Mar. 31, 2021																																36,937	10,341,716
Balances at Mar. 31, 2021																																	$ 1	$ 253,156	$ (225,617)		$ 27,540
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (5,791,000)	$ (6,310,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts	65,000	74,000
Depreciation and amortization	328,000	323,000
Stock-based compensation	810,000	710,000
Non-cash interest expense	142,000	127,000
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities		5,000
Loss from minority interest in limited liability company	76,000	182,000
Loss on disposal of property and equipment	9,000
Modification of warrants	287,000
Changes in assets and liabilities:
Accounts receivable	369,000	220,000
Inventory	396,000	313,000
Prepaid expenses and other current assets	253,000	243,000
Other noncurrent assets	150,000	417,000
Accounts payable	276,000	654,000
Accrued and other liabilities	(727,000)	(2,654,000)
Other noncurrent liabilities	104,000	(40,000)
Net cash used in operating activities	(3,253,000)	(5,736,000)
Cash flows from investing activities:
Purchase of property and equipment	(85,000)	(161,000)
Net cash used in investing activities	(85,000)	(161,000)
Cash flows from financing activities:
Proceeds from January 2021 Offering, net of issuance costs	25,122,000
Proceeds from exercise of common warrants	179,000	1,661,000
Net cash provided by financing activities	25,261,000	1,631,000
Net increase (decrease) in cash and cash equivalents	21,923,000	(4,266,000)
Cash and cash equivalents - beginning of period	6,523,000	13,308,000
Cash and cash equivalents - end of period	28,446,000	9,042,000
Supplemental disclosure:
Cash paid for interest
Cash paid for income taxes
Supplemental disclosure of cash flow information as of end of period:
Issuance of Series B convertible preferred stock in settlement of dividends	1,118,000	989,000
Issuance of note payable in settlement of accrued interest	141,000	126,000
Net transfer of equipment between inventory and property and equipment	(191,000)	89,000
Operating cash outflows from operating leases	75,000	75,000
Purchase Agreement with LPC [Member]
Cash flows from financing activities:
Transaction costs in connection with Purchase Agreement with LPC	(40,000)
November 2019 Offering [Member]
Cash flows from financing activities:
Transaction costs in connection with Purchase Agreement with LPC		$ (30,000)

Note 1 - The Company and Basis

Note 1 - The Company and Basis of Presentation	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. The Company and Basis of Presentation Viveve Medical, Inc. (“Viveve Medical”, the “Company”, “we”, “our”, or “us”) designs, develops, manufactures and markets a platform medical technology, which we refer to as Cryogen-cooled Monopolar RadioFrequency 2021 On January 19, 2021, “January 2021 $27,600,000, The offering comprised of: ( 1 4,607,940 $3.40 one one one $3.40 fifth 2 2,450,880 $3.40 one one one $3.40 fifth 1,058,820 1,058,820 $25,122,000. A total of 2,450,880 January 2021 January 2021, no Warrants to purchase a total of 8,117,640 January 2021 February March 2021, January 2021 12,760 $43,000. March 31, 2021, January 2021 8,104,880 Series C Convertible Preferred Stock In connection with the closing of the January 2021 With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder's option into one All Series C convertible preferred stock have been converted into common stock and there are no November 2019 Amendment to Warrant Pricing Terms On January 19, 2021, $3.40 2 2 one $3.40. $6.10 $3.40 2 2 $6.371 $3.40 no $287,000. Elimination of Series A Convertible Preferred Stock On December 16, 2020, 547,345 $0.0001 November 25, 2019. no 547,345 Purchase Agreement with Lincoln Park Capital, LLC The Company previously entered into a purchase agreement on June 8, 2020 ( $10,000,000 30 301,762 December 2020), 19.99% $6.46 On March 31, 2021, first 2,068,342 19.99% $2.99 2020 On April 15, 2020, $15.50 $6.10 April 16, 2020, 482,059 24,279 $3,089,000. 2 482,059 2 24,279 $6.371 five April 20, 2020. 2020 $334,000. 11 2 2 March 31, 2021, 2 392,830 2 20,380 Interim Unaudited Financial Information The accompanying unaudited condensed consolidated financial statements of Viveve Medical have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and pursuant to the instructions to Form 10 8 03 X. not The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Annual Report on Form 10 December 31, 2020, March 18, 2021. three March 31,2021 not December 31, 2021 Liquidity and Management Plans The Company has adopted the Financial Accounting Standards Board's (“FASB”) Accounting Standard Codification (“ASC”) Topic 205 40, one The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. However, since inception, the Company has sustained significant operating losses and such losses are expected to continue for the foreseeable future. The Company had an accumulated deficit of $225,617,000 March 31, 2021. $3,253,000 three March 31, 2021. $25,261,000 three March 31,2021 $25,122,000 January 2021 $179,000 March 31, 2021, $28,446,000 $29,598,000. twelve May 2022; may To fund further operations, the Company may may no not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation. Reverse Stock Split - December 2020 The Company effected a 1 10 December 1, 2020. ten one 75,000,000 As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the effective date will be reduced proportionately. The Company issued 5,931 No All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10 Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may, Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2021, one 17% three March 31, 2020, one 48% There were no 10% three March 31, 2021and 2020. As of March 31, 2021, one 18% December 31, 2020, one 37% Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $126,000 March 31, 2021 $124,000 December 31, 2020. During the three March 31, 2021, $64,000 no three March 31, 2020. Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. three March 31, 2021 2020, $366,000 $421,000, March 31, 2021 December 31, 2020, $274,000 $345,000, three March 31, 2021, $230,000 December 31, 2020. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Asia Pacific, Europe, the Middle East and Latin America. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2021 December 31, 2020. $16,000 $17,000 not March 31, 2021 December 31, 2020, Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2021 2020, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $33,000 $32,000 March 31, 2021 December 31, 2020, three March 31, 2021 2020, $14,000 $198,000, no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 North America $ 925 $ 688 Asia Pacific 519 597 Europe and Middle East 6 5 Latin America - 14 Total $ 1,450 $ 1,304 The Company determines geographic location of its revenue based upon the destination of the shipments of its products. Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2021 2020. Product Warranty The Company's products sold to customers are generally subject to warranties between one three not Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees. Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2021 2020, Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Three Months Ended March 31, 2021 2020 Convertible preferred stock: Series A convertible preferred stock (a) - - Series B convertible preferred stock (b) 2,414,183 2,135,098 Series C convertible preferred stock (c) - - Warrants to purchase common stock 9,793,605 2,366,591 Stock options to purchase common stock 981,551 1,043,319 Deferred restricted common stock units 687,000 - Deferred restricted common stock awards 232 277 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one March 31, 2020, no December 2020, (b) As of March 31, 2021 2020, 36,937 32,677 2,414,183 2,135,098 1 65.36 $1,000 $15.30 not (c) Each share of Series C preferred stock is convertible at any time at the holder's option into one March 31, 2021, no Recently Issued and Adopted Accounting Standards In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurements	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair Value Measurements The Company recognizes and discloses the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 3 Level 1 Inputs used to measure fair value are unadjusted quoted prices that are available in active markets for the identical assets or liabilities as of the reporting date. Therefore, determining fair value for Level 1 not not Level 2 Pricing is provided by third not Level 3 Inputs used to measure fair value are unobservable inputs that are supported by little or no 3 Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company's assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. There were no March 31, 2021 December 31, 2020. The carrying amounts of the Company's financial assets and liabilities, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses as of March 31, 2021, December 31, 2020 There were no

Note 4 - Investment in Limited

Note 4 - Investment in Limited Liability Company	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Equity Method Investments and Joint Ventures Disclosure [Text Block]	4. Investment in Limited Liability Company On August 8, 2017, Under the terms of the Distributorship Agreement, ICM agreed to not third not three March 31, 2021 2020, zero 120 $0 $10,000, March 31, 2021, 5,285 $0 $10,000 three March 31, 2021 2020, no March 31, 2021 December 31, 2020. In connection with the Distributorship Agreement, the Company also entered into a Membership Unit Subscription Agreement with ICM and the associated limited liability company operating agreement of ICM, pursuant to which the Company invested $2,500,000 not March 31, 2021, 7% three three March 31,2021 2020, $76,000 $182,000, In February 2019, no

Note 5 - Accrued Liabilities

Note 5 - Accrued Liabilities	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	5. Accrued Liabilities Accrued liabilities consisted of the following as of March 31,2021 December 31, 2020 ( March 31, December 31, 2021 2020 Accrued payroll and other related expenses $ 438 $ 473 Deferred revenue - subscription rental program 274 345 Accrued bonuses 265 744 Accrued professional fees 256 290 Accrued clinical trial costs 192 91 Current operating lease liabilities 183 132 Customer advances 78 14 Accrued inventory - 87 Other accruals 187 240 Total accrued liabilities $ 1,873 $ 2,416

Note 6 - Note Payable

Note 6 - Note Payable	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	6. Note Payable On May 22, 2017, December 12, 2017 November 29, 2018 ( “2017 $20,000,000 $10,000,000 $30,000,000 December 29, 2017, $10,000,000 On November 12, 2019, 2017 No. 3” $28,981,000 $31,300,000. 31,300 989,379 5 120% $15.30 $18.36 11 one The Amendment No. 3 2017 ● repayment provisions were amended such that repayment is permitted only with, or after, the redemption in full of the Series B convertible preferred stock issued to CRG; ● the interest only payment period and the period during which the Company may 23rd first no 2017 ● modified certain of the covenants, including (i) to permit issuance of the Series B convertible preferred stock and any preferred stock issued in the equity financing and the exercise and performance by the Company of its rights and obligations in connection with such CRG preferred stock and any preferred stock issued in the equity financing, (ii) eliminate the Company's ability to enter into permitted acquisitions, (iii) further restrict the incurrence of additional indebtedness and removal of the equity cure right, and (iv) eliminate the minimum revenue requirement; and ● the back-end facility fee on the aggregate remaining principal balance on the term loan shall be increased from 5% 25%. Pursuant to the Amendment No. 3, $141,000 $126,000 three March 31, 2021 2020, As of March 31, 2021, As of March 31, 2021 December 31, 2020, $4,660,000 $4,518,000, March 31, 2023. As of March 31, 2021, Year Ending December 31, 2021 (remaining 9 months) $ - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,324 ) Present value of obligations 4,668 Less: Unamortized debt discount (8 ) Note payable, noncurrent portion $ 4,660

Note 7 - Paycheck Protection Pr

Note 7 - Paycheck Protection Program Loan	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Long-term Debt [Text Block]	7. Paycheck Protection Program Loan The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 24, 2020, $1,343,000 1.00% two ten may No In October 2020, 8 24 six 10 16 no two October 2020. no In April 2021, As of March 31, 2021, Year Ending December 31, 2021 (remaining 9 months) $ 877 2022 487 Total payments 1,364 Less: Amount representing interest (21 ) Present value of obligations 1,343 PPP Loan,current portion 1,246 PPP Loan, noncurrent portion $ 97

Note 8 - Leases

Note 8 - Leases	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	8. Leases Lessee: The following information pertains to those operating lease agreements where the Company is the lessee. On February 1, 2017, 12,400 January 26, 2017. June 1, 2017 May 2021. June 2017. The monthly base rent under the Sublease was equal to $20.50 first $21.12 $21.75 second third $22,000. $88,000 In March 2021, 34 March 31, 2024. second third $21,028, $21,643 $22,258 June 2021. $19,000. In September 2018, 36 September 20, 2018. $3,000. Operating lease rentals are expensed on a straight-line basis over the life of the lease beginning on the date the Company takes possession of the property. At lease inception, the Company determines the lease term by assuming the exercise of those renewal options that are reasonably assured. The lease term is used to determine whether a lease is financing or operating and is used to calculate straight-line rent expense. Additionally, the depreciable life of leasehold improvements is limited by the expected lease term. Leases with an initial term of 12 not The following table reflects the Company's lease assets and lease liabilities at March 31, 2021 December 31, 2020 ( March 31, December 31, 2021 2020 Assets: Operating lease right-of-use assets $ 678 $ 130 Liabilities: Current operating lease liabilities $ 183 $ 132 Noncurrent operating lease liabilities 495 - $ 678 $ 132 The operating lease right-of-use assets are included in other assets on the condensed consolidated balance sheets. The operating lease liabilities are included in accrued liabilities and other noncurrent liabilities on the condensed consolidated balance sheets. The operating leases expense for the three March 31, 2021 2020 $73,000 $76,000, As of March 31, 2021, Year Ending December 31, 2021 (remaining 9 months) $ 189 2022 279 2023 285 2024 67 Total lease payments 820 Less: Amount representing interest (142 ) Present value of lease liabilities $ 678 The weighted average remaining lease term was approximately 35 March 31, 2021. three March 31, 2021 12.5%. Lessor: The following information pertains to those operating lease agreements where the Company is the lessor. As of March 31, 2021, Year Ending December 31, 2021 (remaining 9 months) $ 274 Thereafter - Total $ 274 As of March 31, 2021, $709,000 three March 31, 2021 2020 $110,000 $113,000,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments and Contingencies Indemnification Agreements The Company enters into standard indemnification arrangements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with performance of services within the scope of the agreement, breach of the agreement by the Company, or noncompliance of regulations or laws by the Company, in all cases provided the indemnified party has not not not Loss Contingencies The Company is or has been subject to proceedings, lawsuits and other claims arising in the ordinary course of business. The Company evaluates contingent liabilities, including threatened or pending litigation, for potential losses. If the potential loss from any claim or legal proceeding is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Because of uncertainties related to these matters, accruals are based upon the best information available. For potential losses for which there is a reasonable possibility (meaning the likelihood is more than remote but less than probable) that a loss exists, the Company will disclose an estimate of the potential loss or range of such potential loss or include a statement that an estimate of the potential loss cannot be made. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation and may not

Note 10 - Preferred Stock

Note 10 - Preferred Stock	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Preferred Stock [Text Block]	10. Preferred Stock Series A Convertible Preferred Stock On December 16, 2020, no 547,345 Series B Convertible Preferred Stock As previously reported (see Note 6 31,300 989,379 In connection with the CRG debt conversion, on November 26, 2019, 12.5% three March 31, 2021, 1,118 $1,000 three March 31, 2020, 989 $1,000 $12,000 5,637 March 31, 2021. As of March 31, 2021 December 31, 2020, 36,937 35,819 2,414,183 2,341,111 1 65.36 $1,000 $15.30 not The shares of Series B convertible preferred stock have no The Series B convertible preferred stock also provides that for so long as any shares are outstanding, the consent of the holders of the Series B convertible preferred stockholders would be required to amend the Company's organizational documents, approve any merger, sale of assets, or other major corporate transaction, or incur additional indebtedness, among other items. Series C Convertible Preferred Stock In connection with the closing of the public offering, on January 19, 2021, With certain exceptions, as described in the Series C Certificate of Designation, the shares of Series C convertible preferred stock have no Each share of Series C convertible preferred stock is convertible at any time at the holder's option into one A total of 2,450,880 January 2021 January 2021, no

Note 11 - Common Stock

Note 11 - Common Stock	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Common Stock Purchase Agreement with Lincoln Park Capital, LLC On June 8, 2020, $10,000,000 30 301,762 December 2020), 19.99% $6.46 five On March 31, 2021, first 2,068,342 19.99% $2.99 five 2021 On January 19, 2021, “January 2021 $27,600,000, The offering comprised of: ( 1 4,607,940 $3.40 one one one $3.40 fifth 2 2,450,880 $3.40 one one one $3.40 fifth 1,058,820 1,058,820 $25,122,000. A total of 2,450,880 January 2021 January 2021, no Warrants to purchase a total of 8,117,640 January 2021 February March 2021, January 2021 12,760 $43,000. March 31, 2021, January 2021 8,104,880 Restricted Common Shares There were no three March 31, 2021. The activity of restricted common shares during the three March 31, 2020 ● In March 2020, 28,313 $24,000. Warrants for Common Stock As of March 31,2021, Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 3.40 285,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 3.40 413,210 January 2021 Common Shares January 19, 2026 $ 3.40 8,104,880 9,793,605 In connection with the 2017 223, $9,500.00 ten three March 31, 2021 2020, $1,000 $1,000, March 31, 2021, $8,000. In February 2020, 102,626 $1,591,000, 4,548 $70,000. In connection with the January 2021 8,117,640 one $3.40 fifth On January 19, 2021, $3.40 2 2 one $3.40. $6.10 $3.40 2 2 $6.371 $3.40 no 2 2 $287,000 Immediately Immediately Series B Warrants before Modification After Modification Exercise price Common stock price $6.10 $3.40 Common stock price $3.19 $3.19 Expected term (in years) 3.9 3.9 Average volatility 90% 90% Risk-free interest rate 0.33% 0.33% Dividend yield 0% 0% Immediately Immediately Series A-2 and B-2 Warrants before Modification After Modification Exercise price $6.37 $3.40 Common stock price $3.19 $3.19 Expected term (in years) 4.3 4.3 Average volatility 90% 90% Risk-free interest rate 0.33% 0.33% Dividend yield 0% 0% The incremental fair value of the Series B, A- 2 2 In February 2021, 40,000 $136,000 8,760 January 2021 $30,000. In March 2021, 4,000 January 2021 $13,000. As of March 31, 2021, no 285,632 As of March 31, 2021, 2 392,830 2 20,380 As of March 31, 2021, January 2021 8,104,880 No three March 31, 2021 2020. No three March 31, 2021 2020.

Note 12 - Summary of Stock Opti

Note 12 - Summary of Stock Options	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	12. Summary of Stock Options Stock Option Plans The Company has issued equity awards in the form of stock options (both incentive stock options and non-qualified stock options) and deferred restricted stock awards or units, from two 2006 “2006 2013 “2013 As of March 31, 2021, 2006 12 no $9,920.00 1.8 In January 2021, 2013 307,705 1,451,246 1,758,951 2013 As of March 31, 2021, 2013 981,539 91,755 $18.29 8.8 Activity under the 2006 2013 Three Months Ended March 31, 2021 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 986,399 $ 19.10 8.9 $ 675 Options granted 7,000 $ 3.25 Options exercised - Options canceled (11,848 ) $ 66.81 Options outstanding, end of period 981,551 $ 18.42 8.8 $ - Vested and exercisable and expected to vest, end of period 928,262 $ 18.96 8.8 $ - Vested and exercisable, end of period 294,253 $ 38.04 8.6 $ - The aggregate intrinsic value reflects the difference between the exercise price of the underlying stock options and the Company's closing share price as of March 31, 2021. The options outstanding and exercisable as of March 31, 2021 Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2021 Price Term (Years) March 31, 2021 Price $3.06 - $8.91 962,600 $ 8.28 8.8 284,952 $ 8.67 $10.90 - $13.60 15,500 $ 12.64 8.9 6,490 $ 12.98 $380.00 - $580.00 125 $ 552.00 8.2 116 $ 563.62 $1,000.00 - $1,970.00 1,888 $ 1,432.98 7.6 1,395 $ 1,438.84 $2,020.00 - $2,830.00 71 $ 2,521.55 6.2 55 $ 2,528.73 $3,110.00 - $3,580.00 189 $ 3,439.26 7.4 157 $ 3,453.69 $4,360.00 - $4,970.00 595 $ 4,552.59 6.2 517 $ 4,555.78 $5,010.00 - $5,670.00 294 $ 5,373.27 6.1 284 $ 5,365.88 $6,000.00 - $6,000.00 138 $ 6,000.00 4.7 138 $ 6,000.00 $7,140.00 - $7,920.00 139 $ 7,722.73 5.6 137 $ 7,720.15 $9,920.00 - $9,920.00 12 $ 9,920.00 1.8 12 $ 9,920.00 Total: 981,551 $ 18.42 8.8 294,253 $ 38.04 Deferred Restricted Stock Units As of March 31, 2021, 687,000 2013 In January 2021, 690,000 2013 second During the three March 31, 2021, 3,000 2013 During the three March 31, 2020, no 2013 Deferred Restricted Stock Awards As of March 31, 2021, 232 2013 During the three March 31, 2021 2020, no 2013 2017 In September 2020, 2017 “2017 twelfth September 30, 2020. As of March 31, 2021, 2017 22 Stock-Based Compensation During the three March 31, 2021, 7,000 $2.19 three March 31, 2020, 46,800 $8.80 no three March 31, 2021 2020. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of stock options is being amortized on a straight-line basis over the requisite service period of the awards. The fair value of stock options granted was estimated using the following weighted average assumptions: Three Months Ended March 31, 2021 2020 Expected term (in years) 5 5 Average volatility 87 % 73 % Risk-free interest rate 0.82 % 0.45 % Dividend yield 0 % 0 % Option-pricing models require the input of various subjective assumptions, including the option's expected life and the price volatility of the underlying stock. The expected stock price volatility is based on analysis of the Company's stock price history over a period commensurate with the expected term of the options, trading volume of comparable companies' stock, look-back volatilities and the Company specific events that affected volatility in a prior period. The expected term of stock options represents the weighted average period the stock options are expected to remain outstanding and is based on the history of exercises and cancellations on all past option grants made by the Company, the contractual term, the vesting period and the expected remaining term of the outstanding options. The risk-free interest rate is based on the U.S. Treasury interest rates whose term is consistent with the expected life of the stock options. No not not The following table shows stock-based compensation expense included in the condensed consolidated statements of operations for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 Cost of revenue $ 55 $ 60 Research and development 97 86 Selling, general and administrative 658 564 Total $ 810 $ 710 As of March 31, 2021, $4,186,000. 2.3 As of March 31, 2021, $2,011,000. 1.8

Note 13 - Income Taxes

Note 13 - Income Taxes	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes No no For interim periods, the Company estimates its annual effective income tax rate and applies the estimated rate to the year-to-date income or loss before income taxes. The Company also computes the tax provision or benefit related to items reported separately and recognizes the items net of their related tax effect in the interim periods in which they occur. The Company also recognizes the effect of changes in enacted tax laws or rates in the interim periods in which the changes occur. The Company's effective tax rate is 0% three March 31, 2021 2020. 2021 0%. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020

Note 14 - Related Party Transac

Note 14 - Related Party Transactions	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	14. Related Party Transactions In June 2006, October 4, 2007. 300 March 31, 2021, 855 38 $77,000 $282,000 three March 31, 2021 2020, March 31, 2021 December 31, 2020 $1,000 $9,000, In August 2017, February 2019, no 5

Note 15 - Subsequent Events

Note 15 - Subsequent Events	3 Months Ended
	Mar. 31, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	15. Subsequent Events Purchase Agreement with Lincoln Park Capital, LLC In May 2021, 250,000 $2.817 $704,000. November 2019 Amendment to Warrant Pricing Terms As a result of the common stock sales to LPC, the Company reduced the exercise price of its Series B, A- 2 2 $3.40 $2.817 no

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Financial Statement Presentation The condensed consolidated financial statements include the accounts of the Company and our wholly-owned subsidiaries, Viveve, Inc. and Viveve BV. All significant intercompany accounts and transactions have been eliminated in consolidation.
Reserve Stock Split, Policy [Policy Text Block]	Reverse Stock Split - December 2020 The Company effected a 1 10 December 1, 2020. ten one 75,000,000 As a result of the reverse stock split, proportionate adjustments were made to the per share exercise price and/or the number of shares issuable upon the exercise or vesting of all then outstanding stock options, deferred restricted stock awards and warrants, which will result in a proportional decrease in the number of shares of the Company's common stock reserved for issuance upon exercise or vesting of such stock options, deferred restricted stock awards and warrants, and, in the case of stock options and warrants, a proportional increase in the exercise price of all such stock options and warrants. In addition, the number of shares reserved for issuance under the Company's equity compensation plans immediately prior to the effective date will be reduced proportionately. The Company issued 5,931 No All of the share numbers, share prices, and exercise prices have been adjusted, on a retroactive basis, to reflect this 1 10
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses and the related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not may
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments purchased with an original maturity of three one may,
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties To achieve profitable operations, the Company must successfully develop, manufacture, and market its products. There can be no Most of the Company's products to date require clearance or approvals from the U.S. Food and Drug Administration (“FDA”) or other international regulatory agencies prior to commencing commercial sales. There can be no The Company is subject to risks common to companies in the medical device industry including, but not The Company designs, develops, manufactures and markets a medical device that it refers to as the Viveve System, which is intended for the non-invasive treatment of vaginal introital laxity, for improved sexual function, for vaginal rejuvenation, for use in general surgical procedures for electrocoagulation and hemostasis, and stress urinary incontinence, depending on the relevant country-specific clearance or approval. The Viveve System consists of three four five third In North America, the Company sells its products primarily through a direct sales force to health care practitioners. Outside North America, the Company sells through an extensive network of distribution partners. During the three March 31, 2021, one 17% three March 31, 2020, one 48% There were no 10% three March 31, 2021and 2020. As of March 31, 2021, one 18% December 31, 2020, one 37%
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable are recorded at the invoiced amount and are not six may six not $126,000 March 31, 2021 $124,000 December 31, 2020. During the three March 31, 2021, $64,000 no three March 31, 2020.
Revenue from Contract with Customer [Policy Text Block]	Revenue from Contracts with Customers Revenue consists primarily of the sale of the Viveve System, single-use treatment tips and ancillary consumables. The Company applies the following five 1 2 3 4 5 Rental revenue is generated through the lease of the Viveve System. The Company's operating leases for the Viveve System generally have a rental period of six nine June 30, 2019. three March 31, 2021 2020, $366,000 $421,000, March 31, 2021 December 31, 2020, $274,000 $345,000, three March 31, 2021, $230,000 December 31, 2020. Late in the first 2020, 19 70 80% three 19 In connection with the lease of the Viveve System, the Company offers single-use treatment tips and ancillary consumables that are considered non-lease components. In the contracts with lease and non-lease components, the Company follows the relevant guidance in ASC 606, Sales of our products are subject to regulatory requirements that vary from country to country. The Company has regulatory clearance for differing indications, or can sell its products without a clearance, in many countries throughout the world, including countries within the following regions: North America, Asia Pacific, Europe, the Middle East and Latin America. In North America, we market and sell primarily through a direct sales force. Outside of North America, we market and sell primarily through distribution partners. The Company does not Customer Advance Payments From time to time, customers will pay for a portion of the products ordered in advance. Upon receipt of such payments, the Company records the customer advance payment as a component of accrued liabilities. The Company will remove the customer advance payment from accrued liabilities when revenue is recognized upon shipment of the products. Contract Assets and Liabilities The Company continually evaluates whether the revenue generating activities and advanced payment arrangements with customers result in the recognition of contract assets or liabilities. No March 31, 2021 December 31, 2020. $16,000 $17,000 not March 31, 2021 December 31, 2020, Separately, accounts receivable, net represents receivables from contracts with customers. Significant Financing Component The Company applies the practical expedient to not not one three March 31, 2021 2020, not Contract Costs The Company began its rental program in the quarter ended June 30, 2019. $33,000 $32,000 March 31, 2021 December 31, 2020, three March 31, 2021 2020, $14,000 $198,000, no one Shipping and Handling Shipping costs billed to customers are recorded as revenue. Shipping and handling expense related to costs incurred to deliver product are recognized within cost of goods sold. The Company accounts for shipping and handling activities that occur after control has transferred as a fulfillment cost as opposed to a separate performance obligation, and the costs of shipping and handling are recognized concurrently with the related revenue. Revenue by Geographic Area Management has determined that the sales by geography is a key indicator for understanding the Company's financials because of the different sales and business models that are required in the various regions of the world (including regulatory, selling channels, pricing, customers and marketing efforts). The following table presents the revenue from unaffiliated customers disaggregated by geographic area for the three March 31, 2021 2020 Three Months Ended March 31, 2021 2020 North America $ 925 $ 688 Asia Pacific 519 597 Europe and Middle East 6 5 Latin America - 14 Total $ 1,450 $ 1,304 The Company determines geographic location of its revenue based upon the destination of the shipments of its products.
Equity Method Investments [Policy Text Block]	Investments in Unconsolidated Affiliates The Company uses the equity method to account for its investments in entities that it does not 1 2 3 three not The Company assesses the potential impairment of the equity method investments when indicators such as a history of operating losses, a negative earnings and cash flow outlook, and the financial condition and prospects for the investee's business segment might indicate a loss in value. The carrying value of the investments is reviewed annually for changes in circumstances or the occurrence of events that suggest the investment may not No three March 31, 2021 2020.
Standard Product Warranty, Policy [Policy Text Block]	Product Warranty The Company's products sold to customers are generally subject to warranties between one three not
Share-based Payment Arrangement [Policy Text Block]	Accounting for Stock-Based Compensation Share-based compensation cost is measured at grant date, based on the fair value of the award, and is recognized as expense over the employee's service period. The Company recognizes compensation expense on a straight-line basis over the requisite service period of the award. The Company determined that the Black-Scholes option pricing model is the most appropriate method for determining the estimated fair value for stock options and purchase rights under the employee stock purchase plan. The Black-Scholes option pricing model requires the use of highly subjective and complex assumptions which determine the fair value of share-based awards, including the option's expected term and the price volatility of the underlying stock. Equity instruments issued to nonemployees are recorded in the same manner as similar instruments issued to employees.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Loss Comprehensive loss represents the changes in equity of an enterprise, other than those resulting from stockholder transactions. Accordingly, comprehensive loss may three March 31, 2021 2020,
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share The Company's basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share is computed by giving effect to all potentially dilutive common stock equivalents outstanding during the period. For purposes of this calculation, stock options and warrants to purchase common stock and restricted common stock awards are considered common stock equivalents. For periods in which the Company has reported net losses, diluted net loss per share is the same as basic net loss per share since dilutive common shares are not The following securities were excluded from the calculation of net loss per share because the inclusion would be anti-dilutive: Three Months Ended March 31, 2021 2020 Convertible preferred stock: Series A convertible preferred stock (a) - - Series B convertible preferred stock (b) 2,414,183 2,135,098 Series C convertible preferred stock (c) - - Warrants to purchase common stock 9,793,605 2,366,591 Stock options to purchase common stock 981,551 1,043,319 Deferred restricted common stock units 687,000 - Deferred restricted common stock awards 232 277 (a) Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one March 31, 2020, no December 2020, (b) As of March 31, 2021 2020, 36,937 32,677 2,414,183 2,135,098 1 65.36 $1,000 $15.30 not (c) Each share of Series C preferred stock is convertible at any time at the holder's option into one March 31, 2021, no
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued and Adopted Accounting Standards In December 2019, 2019 12, 740 December 15, 2020, January 1, 2021, not We have reviewed other recent accounting pronouncements and concluded they are either not no

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Three Months Ended March 31, 2021 2020 North America $ 925 $ 688 Asia Pacific 519 597 Europe and Middle East 6 5 Latin America - 14 Total $ 1,450 $ 1,304
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2021 2020 Convertible preferred stock: Series A convertible preferred stock (a) - - Series B convertible preferred stock (b) 2,414,183 2,135,098 Series C convertible preferred stock (c) - - Warrants to purchase common stock 9,793,605 2,366,591 Stock options to purchase common stock 981,551 1,043,319 Deferred restricted common stock units 687,000 - Deferred restricted common stock awards 232 277

Note 5 - Accrued Liabilities (T

Note 5 - Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	March 31, December 31, 2021 2020 Accrued payroll and other related expenses $ 438 $ 473 Deferred revenue - subscription rental program 274 345 Accrued bonuses 265 744 Accrued professional fees 256 290 Accrued clinical trial costs 192 91 Current operating lease liabilities 183 132 Customer advances 78 14 Accrued inventory - 87 Other accruals 187 240 Total accrued liabilities $ 1,873 $ 2,416

Note 6 - Note Payable (Tables)

Note 6 - Note Payable (Tables)	3 Months Ended
	Mar. 31, 2021
The 2017 Loan Agreement [Member]
Notes Tables
Schedule of Debt [Table Text Block]	Year Ending December 31, 2021 (remaining 9 months) $ - 2022 - 2023 5,992 Total payments 5,992 Less: Amount representing interest (1,324 ) Present value of obligations 4,668 Less: Unamortized debt discount (8 ) Note payable, noncurrent portion $ 4,660

Note 7 - Paycheck Protection _2

Note 7 - Paycheck Protection Program Loan (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	Year Ending December 31, 2021 (remaining 9 months) $ 877 2022 487 Total payments 1,364 Less: Amount representing interest (21 ) Present value of obligations 1,343 PPP Loan,current portion 1,246 PPP Loan, noncurrent portion $ 97

Note 8 - Leases (Tables)

Note 8 - Leases (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Lessee, Lease Assets and Liabilities [Table Text Block]	March 31, December 31, 2021 2020 Assets: Operating lease right-of-use assets $ 678 $ 130 Liabilities: Current operating lease liabilities $ 183 $ 132 Noncurrent operating lease liabilities 495 - $ 678 $ 132
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Year Ending December 31, 2021 (remaining 9 months) $ 189 2022 279 2023 285 2024 67 Total lease payments 820 Less: Amount representing interest (142 ) Present value of lease liabilities $ 678
Lessor, Operating Lease, Payment to be Received, Fiscal Year Maturity [Table Text Block]	Year Ending December 31, 2021 (remaining 9 months) $ 274 Thereafter - Total $ 274

Note 11 - Common Stock (Tables)

Note 11 - Common Stock (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Shares Outstanding Exercisable Expiration Exercise Under Issuance Date for Date Price Warrants February 2015 Common Shares February 17, 2025 $ 4,000.00 79 March 2015 Common Shares March 26, 2025 $ 2,720.00 2 May 2015 Common Shares May 12, 2025 $ 4,240.00 37 December 2015 Common Shares December 16, 2025 $ 5,600.00 31 April 2016 Common Shares April 1, 2026 $ 6,080.00 25 May 2016 Common Shares May 11, 2021 $ 7,740.00 6 June 2016 Common Shares June 20, 2026 $ 4,980.00 101 May 2017 Common Shares May 25, 2027 $ 9,500.00 223 November 2019 Common Shares November 26, 2024 $ 3.40 285,632 November 2019 Common Shares November 26, 2024 $ 18.36 989,379 April 2020 Common Shares April 21, 2025 $ 3.40 413,210 January 2021 Common Shares January 19, 2026 $ 3.40 8,104,880 9,793,605
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Immediately Immediately Series B Warrants before Modification After Modification Exercise price Common stock price $6.10 $3.40 Common stock price $3.19 $3.19 Expected term (in years) 3.9 3.9 Average volatility 90% 90% Risk-free interest rate 0.33% 0.33% Dividend yield 0% 0% Immediately Immediately Series A-2 and B-2 Warrants before Modification After Modification Exercise price $6.37 $3.40 Common stock price $3.19 $3.19 Expected term (in years) 4.3 4.3 Average volatility 90% 90% Risk-free interest rate 0.33% 0.33% Dividend yield 0% 0%

Note 12 - Summary of Stock Op_2

Note 12 - Summary of Stock Options (Tables)	3 Months Ended
	Mar. 31, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Three Months Ended March 31, 2021 Weighted Weighted Average Number Average Remaining Aggregate of Exercise Contractual Intrinsic Shares Price Term (years) Value Options outstanding, beginning of period 986,399 $ 19.10 8.9 $ 675 Options granted 7,000 $ 3.25 Options exercised - Options canceled (11,848 ) $ 66.81 Options outstanding, end of period 981,551 $ 18.42 8.8 $ - Vested and exercisable and expected to vest, end of period 928,262 $ 18.96 8.8 $ - Vested and exercisable, end of period 294,253 $ 38.04 8.6 $ -
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Number Weighted Average Number Weighted Outstanding Average Remaining Exercisable Average Range of as of Exercise Contractual as of Exercise Exercise Prices March 31, 2021 Price Term (Years) March 31, 2021 Price $3.06 - $8.91 962,600 $ 8.28 8.8 284,952 $ 8.67 $10.90 - $13.60 15,500 $ 12.64 8.9 6,490 $ 12.98 $380.00 - $580.00 125 $ 552.00 8.2 116 $ 563.62 $1,000.00 - $1,970.00 1,888 $ 1,432.98 7.6 1,395 $ 1,438.84 $2,020.00 - $2,830.00 71 $ 2,521.55 6.2 55 $ 2,528.73 $3,110.00 - $3,580.00 189 $ 3,439.26 7.4 157 $ 3,453.69 $4,360.00 - $4,970.00 595 $ 4,552.59 6.2 517 $ 4,555.78 $5,010.00 - $5,670.00 294 $ 5,373.27 6.1 284 $ 5,365.88 $6,000.00 - $6,000.00 138 $ 6,000.00 4.7 138 $ 6,000.00 $7,140.00 - $7,920.00 139 $ 7,722.73 5.6 137 $ 7,720.15 $9,920.00 - $9,920.00 12 $ 9,920.00 1.8 12 $ 9,920.00 Total: 981,551 $ 18.42 8.8 294,253 $ 38.04
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Three Months Ended March 31, 2021 2020 Expected term (in years) 5 5 Average volatility 87 % 73 % Risk-free interest rate 0.82 % 0.45 % Dividend yield 0 % 0 %
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, 2021 2020 Cost of revenue $ 55 $ 60 Research and development 97 86 Selling, general and administrative 658 564 Total $ 810 $ 710

Note 1 - The Company and Basi_2

Note 1 - The Company and Basis of Presentation (Details Textual) - USD ($)	Jan. 19, 2021	Jun. 08, 2020	Apr. 20, 2020	Apr. 16, 2020	Feb. 28, 2021	Feb. 29, 2020	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Jan. 31, 2021	Jan. 18, 2021	Dec. 31, 2020		Dec. 16, 2020	Dec. 15, 2020	Apr. 15, 2020	Dec. 31, 2019	Nov. 30, 2019
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							9,793,605	9,793,605
Proceeds from Warrant Exercises								$ 179,000	$ 1,661,000
Fair Value Adjustment of Warrants								$ 287,000
Preferred Stock, Shares Authorized (in shares)							10,000,000	10,000,000				10,000,000	[1]
Payments of Warrant Issuance Costs			$ 334,000
Retained Earnings (Accumulated Deficit), Ending Balance							$ (225,617,000)	$ (225,617,000)				$ (219,826,000)	[2]
Net Cash Provided by (Used in) Operating Activities, Total								(3,253,000)	(5,736,000)
Net Cash Provided by (Used in) Financing Activities, Total								25,261,000	$ 1,631,000
Cash and Cash Equivalents, at Carrying Value, Ending Balance							28,446,000	28,446,000				$ 6,523,000	[2]
Working Capital							$ 29,598,000	$ 29,598,000
Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)										1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 3.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	8,117,640						8,104,880	8,104,880		8,117,640
Stock Issued During Period, Shares, Warrant Exercises (in shares)							12,760
Proceeds from Warrant Exercises							$ 43,000
Series A and Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40															$ 6.10	$ 15.50
Proceeds from Warrant Exercises				$ 3,089,000
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40		$ 6.371								$ 6.371
Warrants and Rights Outstanding, Term (Year)			5 years
Fair Value Adjustment of Warrants	$ 287,000
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40										$ 6.10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							285,632	285,632
Stock Issued During Period, Shares, Warrant Exercises (in shares)				24,279	40,000	4,548
Proceeds from Warrant Exercises					$ 136,000	$ 70,000
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)							0	0
Stock Issued During Period, Shares, Warrant Exercises (in shares)				482,059		102,626
Proceeds from Warrant Exercises						$ 1,591,000
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			482,059				392,830	392,830
Stock Issued During Period, Shares, Warrant Exercises (in shares)								392,830
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			24,279				20,380	20,380
Stock Issued During Period, Shares, Warrant Exercises (in shares)								20,380
Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member]
Warrants Per Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40
Warrants and Rights Outstanding, Term (Year)	5 years
Class A Units [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Term (Year)																		5 years
Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member]
Warrants Per Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40
Warrants and Rights Outstanding, Term (Year)	5 years
Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							1	1
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							0	0
Preferred Stock, Par or Stated Value Per Share (in dollars per share)							$ 0.0001	$ 0.0001				$ 0.0001	[1]
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)							1	1
Preferred Stock, Shares Outstanding, Ending Balance (in shares)							0	0						0
Preferred Stock, Shares Authorized (in shares)															547,345
Preferred Stock, Par or Stated Value Per Share (in dollars per share)															$ 0.0001
January 2021 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 27,600,000
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs	$ 25,122,000
Proceeds From Issuance of Common Stock, Net								$ 25,122,000
January 2021 Offering [Member] | Class A Units [Member]
Units Issued, Shares (in shares)	4,607,940
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Common Shares Per Unit (in shares)	1
Warrants Per Unit (in shares)	1
January 2021 Offering [Member] | Class B Units [Member]
Units Issued, Shares (in shares)	2,450,880
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Common Shares Per Unit (in shares)	1
Warrants Per Unit (in shares)	1
Series C Convertible Preferred Stock Per Unit (in shares)	1
January 2021 Offering [Member] | Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	1						1	1
Stock Issued During Period, Shares, New Issues (in shares)	2,450,880
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,058,820
Over-Allotment Option [Member] | Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,058,820
Purchase Agreement with LPC [Member]
Maximum Amount of Shares Issuable		$ 10,000,000
Stock Purchase Agreement Duration Period (Month)		2 years 180 days
Stock Purchase Agreement, Maximum Issuable Shares (in shares)		301,762
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock		19.99%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)		$ 6.46
First Amendment to the LPC Purchase Agreement [Member]
Stock Purchase Agreement, Maximum Issuable Shares (in shares)							2,068,342	2,068,342
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock							19.99%	19.99%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)							$ 2.99	$ 2.99
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.
[2]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual)	Dec. 01, 2020USD ($)shares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Dec. 31, 2020USD ($)shares		Dec. 16, 2020shares
Common Stock, Shares Authorized (in shares) | shares		75,000,000		75,000,000	[1]
Reverse Stock Split, Rounding Adjustment (in shares) | shares	5,931
Payments for Fractional Shares of Reverse Stock Split	$ 0
Number of Financial Institutions		1
Accounts Receivable, Allowance for Credit Loss, Ending Balance		$ 126,000		$ 124,000
Accounts Receivable, Allowance for Credit Loss, Writeoff		64,000	$ 0
Revenue from Contract with Customer, Excluding Assessed Tax, Total		1,450,000	1,304,000
Deferred Income		274,000		345,000
Contract with Customer, Asset, after Allowance for Credit Loss, Total		0		0
Capitalized Contract Cost, Net, Total		33,000		$ 32,000
Capitalized Contract Cost, Amortization		14,000	198,000
Capitalized Contract Cost, Impairment Loss		0
Equity Method Investment, Other than Temporary Impairment		$ 0	$ 0
Series A Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		1
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		0				0
Series B Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		2,414,183	2,135,098	2,341,111
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		36,937	32,677	35,819	[1]
Conversion of Stock Exchange Ratio		65.36
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares		$ 1,000
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares		$ 15.30
Series C Preferred Stock [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares) | shares		1
Preferred Stock, Shares Outstanding, Ending Balance (in shares) | shares		0
Conversion of Stock Exchange Ratio		1
Minimum [Member]
Warranty Period (Year)		1 year
Maximum [Member]
Warranty Period (Year)		3 years
Rental [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total		$ 366,000	$ 421,000
Rental Program Equipment [Member]
Revenue from Contract with Customer, Excluding Assessed Tax, Total		230,000
Marketing Programs [Member]
Contract with Customer, Liability, Total		$ 16,000		$ 17,000
Customer Concentration Risk [Member] | Revenue Benchmark [Member]
Concentration Risk, Number of Customers		1	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | One Customer [Member]
Concentration Risk, Percentage		17.00%	48.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Number of Customers		1		1
Customer Concentration Risk [Member] | Accounts Receivable [Member] | One Customer [Member]
Concentration Risk, Percentage		18.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Two Customers [Member]
Concentration Risk, Percentage				37.00%
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio	10
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Revenue From Unaffiliated Customers by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Revenue	$ 1,450	$ 1,304
North America [Member]
Revenue	925	688
Asia Pacific [Member]
Revenue	519	597
Europe And Middle East [Member]
Revenue	6	5
Latin America [Member]
Revenue		$ 14

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares	3 Months Ended
	Mar. 31, 2021		Mar. 31, 2020
Series A Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		[1]
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	2,414,183	[2]	2,135,098
Series C Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)		[3]
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	9,793,605		2,366,591
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	981,551		1,043,319
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	687,000
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares)	232		277
[1]	Each share of Series A convertible preferred stock was convertible at any time at the holder's option into one share of common stock. As of March 31, 2020, all Series A convertible preferred stock had been converted into common stock and there were no remaining shares outstanding. In December 2020, the Company filed a Certificate of Elimination with the Delaware Secretary of State with respect to the authorized shares of Series A convertible preferred stock.
[2]	As of March 31, 2021 and 2020, a total of 36,937 and 32,677 shares of Series B convertible preferred stock were outstanding and convertible into 2,414,183 and 2,135,098 shares of common stock, respectively. Each share of Series B convertible preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-65.36 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $15.30 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.
[3]	Each share of Series C preferred stock is convertible at any time at the holder's option into one share of common stock. As of March 31, 2021, all Series C convertible preferred stock had been converted into common stock and there are no remaining shares of Series C convertible preferred stock outstanding.

Note 4 - Investment in Limite_2

Note 4 - Investment in Limited Liability Company (Details Textual)	Aug. 08, 2017USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Mar. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Income (Loss) from Equity Method Investments, Total		$ (76,000)	$ (182,000)
InControl Medical [Member]
Equity Method Investment, Ownership Percentage		7.00%		7.00%
Income (Loss) from Equity Method Investments, Total		$ 76,000	$ 182,000
InControl Medical [Member] | Membership Unit Subscription Agreement [Member]
Unrecorded Unconditional Purchase Obligation, Period Quantity Purchased		0	120	5,285
Unrecorded Unconditional Purchase Obligation, Purchases		$ 0	$ 10,000
Payments for Purchase of Products		0	$ 10,000
Accounts Payable, Related Parties, Current		$ 0		$ 0	$ 0
Payments to Acquire Equity Method Investments	$ 2,500,000

Note 5 - Accrued Liabilities -

Note 5 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued payroll and other related expenses	$ 438	$ 473
Deferred revenue - subscription rental program	274	345
Accrued bonuses	265	744
Accrued professional fees	256	290
Accrued clinical trial costs	192	91
Accrued inventory		87
Other accruals	187	240
Total accrued liabilities	1,873	2,416	[1]
Customer Advances [Member]
Contract with customer, liability	78	14
Accrued Liabilities [Member]
Current operating lease liabilities	$ 183	$ 132
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable (Details

Note 6 - Note Payable (Details Textual) - USD ($)	Nov. 12, 2019	Dec. 29, 2017	May 22, 2017	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				9,793,605
Notes Payable, Noncurrent, Total				$ 4,660,000		$ 4,518,000	[1]
Series B Convertible Preferred Stock Into Common Stock [Member] | Minimum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 15.30
Series B Convertible Preferred Stock Into Common Stock [Member] | Maximum [Member]
Conversion of Stock, Conversion Rate (in dollars per share)	$ 18.36
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	989,379
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrants and Rights Outstanding, Exercise Price Percentage of Conversion Rate	120.00%
Conversion of Term Loan with CRG Into Stock and Warrants [Member]
Debt Conversion, Original Debt, Amount	$ 28,981,000
Debt Conversion, Converted Instrument, Amount	$ 31,300,000
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)	31,300
The 2017 Loan Agreement [Member]
Notes Payable, Noncurrent, Total				4,660,000
The 2017 Loan Agreement [Member] | CRG LP [Member]
Debt Instrument, Face Amount			$ 20,000,000
Debt Agreement, Covenant, Additional Funding			10,000,000
Debt Agreement, Maximum Borrowing Capacity			$ 30,000,000
Proceeds from Lines of Credit, Total		$ 10,000,000
Debt Instrument, Back-end Facility Fee Percentage of Principal	25.00%		5.00%
Paid-in-Kind Interest				141,000	$ 126,000
Notes Payable, Noncurrent, Total				$ 4,660,000		$ 4,518,000
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 6 - Note Payable - Summary

Note 6 - Note Payable - Summary of Note Payable (Details) - USD ($)	Mar. 31, 2021	Dec. 31, 2020	[1]
Less: Unamortized debt discount	$ (8,000)
Note payable, noncurrent portion	4,660,000	$ 4,518,000
The 2017 Loan Agreement [Member]
2021 (remaining 9 months)
2022
2023	5,992,000
Total payments	5,992,000
Less: Amount representing interest	(1,324,000)
Present value of obligations	4,668,000
Less: Unamortized debt discount	(8,000)
Note payable, noncurrent portion	$ 4,660,000
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 7 - Paycheck Protection _3

Note 7 - Paycheck Protection Program Loan (Details Textual)	Apr. 24, 2020USD ($)
Paycheck Protection Program CARES Act [Member]
Proceeds from Issuance of Unsecured Debt	$ 1,343,000

Note 7 - Paycheck Protection _4

Note 7 - Paycheck Protection Program Loan - Summary of Paycheck Protection Program Loan (Details) - Paycheck Protection Program CARES Act [Member] $ in Thousands	Mar. 31, 2021USD ($)
2021 (remaining 9 months)	$ 877
2022	487
Total payments	1,364
Less: Amount representing interest	(21)
Present value of obligations	1,343
PPP Loan,current portion	1,246
PPP Loan, noncurrent portion	$ 97

Note 8 - Leases (Details Textua

Note 8 - Leases (Details Textual)	1 Months Ended			3 Months Ended
	Jun. 30, 2021USD ($)	Mar. 31, 2021USD ($)	Sep. 30, 2018USD ($)	Mar. 31, 2021USD ($)	Mar. 31, 2020USD ($)	Feb. 01, 2017USD ($)ft²
Operating Lease, Expense				$ 73,000	$ 76,000
Operating Lease, Weighted Average Remaining Lease Term (Month)		2 years 330 days		2 years 330 days
Operating Lease, Weighted Average Discount Rate, Percent		12.50%		12.50%
Operating Lease, Property Plant and Equipment, Amount		$ 709,000		$ 709,000
Sublease Agreement for Relocation of Headquarters [Member]
Area of Real Estate Property (Square Foot) | ft²						12,400
Operating Leases, Monthly Rent Per Rentable Square Foot During First Year						20.5
Operating Leases, Monthly Rent Per Rentable Square Foot During Second Year						21.12
Operating Leases, Monthly Rent Per Rentable Square Foot During Third Year						21.75
Security Deposit						$ 22,000
Operating Leases, Allowance for Certain Improvements						$ 88,000
Lessee, Operating Lease, Renewal Term (Month)		2 years 300 days		2 years 300 days
Sublease Agreement for Relocation of Headquarters [Member] | Forecast [Member]
Lessee, Operating Lease, Rent Abatement	$ 19,000
Sublease Agreement for Relocation of Headquarters First Year Extension [Member]
Lessee, Operating Lease, Monthly Gross Rent		$ 21,028
Sublease Agreement for Relocation of Headquarters Second Year Extension [Member]
Lessee, Operating Lease, Monthly Gross Rent		21,643
Sublease Agreement for Relocation of Headquarters Third Year Extension [Member]
Lessee, Operating Lease, Monthly Gross Rent		$ 22,258
Noncancelable Operating Lease Agreement for Office Equipment [Member]
Lessee, Operating Lease, Term of Contract (Month)			3 years
Operating Leases, Monthly Payment			$ 3,000
Leases of Viveve Systems [Member]
Lessor, Operating Lease, Depreciation on Leased Assets				$ 110,000	$ 113,000

Note 8 - Leases - Lease Assets

Note 8 - Leases - Lease Assets and Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Operating lease right-of-use assets	$ 678	$ 130
Accrued Liabilities [Member]
Current operating lease liabilities	183	132
Other Noncurrent Liabilities [Member]
Noncurrent operating lease liabilities	495
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Operating Lease, Liability, Total	$ 678	$ 132

Note 8 - Leases - Maturity of O

Note 8 - Leases - Maturity of Operating Lease Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
2021 (remaining 9 months)	$ 189
2022	279
2023	285
2024	67
Total lease payments	820
Less: Amount representing interest	(142)
Accrued Liabilities and Other Noncurrent Liabilities [Member]
Present value of lease liabilities	$ 678	$ 132

Note 8 - Leases - Minimum Futur

Note 8 - Leases - Minimum Future Rentals (Details) $ in Thousands	Mar. 31, 2021USD ($)
2021 (remaining 9 months)	$ 274
Thereafter
Total	$ 274

Note 10 - Preferred Stock (Deta

Note 10 - Preferred Stock (Details Textual)	Jan. 19, 2021shares	Nov. 26, 2019	Nov. 12, 2019shares	Mar. 31, 2021USD ($)$ / sharesshares	Mar. 31, 2020USD ($)shares	Mar. 31, 2021USD ($)$ / sharesshares	Dec. 31, 2020shares		Dec. 16, 2020shares	Dec. 15, 2020shares
Preferred Stock, Shares Authorized (in shares)				10,000,000		10,000,000	10,000,000	[1]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				9,793,605		9,793,605
Warrants Issued Upon Conversion of Term Loan with CRG [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)			989,379
Conversion of Term Loan with CRG Into Series B Convertible Preferred Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued (in shares)			31,300
Series A Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0		0			0
Preferred Stock, Shares Authorized (in shares)										547,345
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				1		1
Series B Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				36,937	32,677	36,937	35,819	[1]
Preferred Stock, Dividend Rate, Percentage		12.50%
Preferred Stock Dividends, Shares (in shares)				1,118	989	5,637
Dividends, Preferred Stock, Cash | $				$ 1,000	$ 1,000	$ 12,000
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				2,414,183	2,135,098	2,414,183	2,341,111
Conversion of Stock Exchange Ratio				65.36
Preferred Stock, Liquidation Preference Per Share (in dollars per share) | $ / shares				$ 1,000		$ 1,000
Conversion of Stock, Conversion Rate (in dollars per share) | $ / shares				$ 15.30		$ 15.30
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0		0
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				1		1
Conversion of Stock Exchange Ratio				1
Series C Preferred Stock [Member] | January 2021 Offering [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)	1			1		1
Stock Issued During Period, Shares, New Issues (in shares)	2,450,880
[1]	The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited consolidated financial statements as of that date.

Note 11 - Common Stock (Details

Note 11 - Common Stock (Details Textual) - USD ($)	Jan. 19, 2021	Jun. 08, 2020	Apr. 16, 2020	Mar. 31, 2021	Feb. 28, 2021	Mar. 31, 2020	Feb. 29, 2020	Mar. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Jan. 31, 2021	Jan. 18, 2021	Apr. 20, 2020	Nov. 30, 2019	May 22, 2017
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				9,793,605				9,793,605	9,793,605
Proceeds from Warrant Exercises									$ 179,000	$ 1,661,000
Stock Issued During Period, Share, Restricted Common Shares (in shares)						28,313			0
Stock Issued During Period, Value, Restricted Common Shares						$ 24,000
Amortization of Debt Discount (Premium)									$ 1,000	1,000
Debt Instrument, Unamortized Discount, Total				$ 8,000				$ 8,000	8,000
Fair Value Adjustment of Warrants									$ 287,000
Class of Warrant or Right Number of Securities Called by Warrants or Rights Cancelled In Period (in shares)									0	0
Class Of Warrant Or Right, Number Of Securities Called By Warrants Or Rights Expired In Period (in shares)									0	0
Series C Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)				0				0	0
Series B Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40											$ 6.10
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				285,632				285,632	285,632
Stock Issued During Period, Shares, Warrant Exercises (in shares)			24,279		40,000		4,548
Proceeds from Warrant Exercises					$ 136,000		$ 70,000
Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)											1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 3.40
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	8,117,640			8,104,880				8,104,880	8,104,880		8,117,640
Stock Issued During Period, Shares, Warrant Exercises (in shares)								12,760
Proceeds from Warrant Exercises								$ 43,000
May 2017 Issuance Related to 2017 Loan Agreement [Member]
Warrants and Rights Outstanding, Term (Year)															10 years
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)															$ 9,500
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)															223
Series A Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				0				0	0
Stock Issued During Period, Shares, Warrant Exercises (in shares)			482,059				102,626
Proceeds from Warrant Exercises							$ 1,591,000
Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Term (Year)													5 years
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40											$ 6.371	$ 6.371
Fair Value Adjustment of Warrants	$ 287,000
January 2021 Offering Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				8,104,880				8,104,880	8,104,880
Stock Issued During Period, Shares, Warrant Exercises (in shares)				4,000	8,760
Proceeds from Warrant Exercises				$ 13,000	$ 30,000
Series A-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				392,830				392,830	392,830				482,059
Stock Issued During Period, Shares, Warrant Exercises (in shares)									392,830
Series B-2 Warrants [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				20,380				20,380	20,380				24,279
Stock Issued During Period, Shares, Warrant Exercises (in shares)									20,380
Class A Units [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Term (Year)														5 years
Class A Units [Member] | Warrants Issued in Connection with Class A Units [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants Per Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40
Class B Units [Member] | Warrants Issued in Connection with Class B Units [Member]
Warrants and Rights Outstanding, Term (Year)	5 years
Warrants Per Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 3.40
Purchase Agreement with LPC [Member]
Maximum Amount of Shares Issuable		$ 10,000,000
Stock Purchase Agreement Duration Period (Month)		2 years 180 days
Stock Purchase Agreement, Maximum Issuable Shares (in shares)		301,762
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock		19.99%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)		$ 6.46
November 2019 Offering [Member] | Class B Units [Member]
Series A Convertible Preferred Stock Per Unit (in shares)														1
First Amendment to the LPC Purchase Agreement [Member]
Stock Purchase Agreement, Maximum Issuable Shares (in shares)				2,068,342				2,068,342	2,068,342
Stock Purchase Agreement, Maximum Issuable Shares, Percent of Outstanding Stock				19.99%				19.99%	19.99%
Stock Purchase Agreement, Share Price Covenant Trigger (in dollars per share)				$ 2.99				$ 2.99	$ 2.99
January 2021 Offering [Member]
Proceeds from Issuance or Sale of Equity, Total	$ 27,600,000
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Proceeds from Issuance or Sale of Equity, Net of Issuance Costs	$ 25,122,000
January 2021 Offering [Member] | Series C Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)	2,450,880
January 2021 Offering [Member] | Class A Units [Member]
Units Issued, Shares (in shares)	4,607,940
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Common Shares Per Unit (in shares)	1
Warrants Per Unit (in shares)	1
January 2021 Offering [Member] | Class B Units [Member]
Units Issued, Shares (in shares)	2,450,880
Shares Issued, Price Per Share (in dollars per share)	$ 3.40
Common Shares Per Unit (in shares)	1
Warrants Per Unit (in shares)	1
Over-Allotment Option [Member]
Stock Issued During Period, Shares, New Issues (in shares)	1,058,820
Over-Allotment Option [Member] | Warrants Issued in Connection with January 2021 Offering [Member]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	1,058,820

Note 11 - Common Stock - Summar

Note 11 - Common Stock - Summary of Outstanding Warrants (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Shares Outstanding Under Warrants (in shares)	9,793,605
Warrant One [Member]
Expiration Date	Feb. 17, 2025
Exercise Price (in dollars per share) | $ / shares	$ 4,000
Shares Outstanding Under Warrants (in shares)	79
Warrant Two [Member]
Expiration Date	Mar. 26, 2025
Exercise Price (in dollars per share) | $ / shares	$ 2,720
Shares Outstanding Under Warrants (in shares)	2
Warrant Three [Member]
Expiration Date	May 12, 2025
Exercise Price (in dollars per share) | $ / shares	$ 4,240
Shares Outstanding Under Warrants (in shares)	37
Warrant Four [Member]
Expiration Date	Dec. 16, 2025
Exercise Price (in dollars per share) | $ / shares	$ 5,600
Shares Outstanding Under Warrants (in shares)	31
Warrant Five [Member]
Expiration Date	Apr. 1, 2026
Exercise Price (in dollars per share) | $ / shares	$ 6,080
Shares Outstanding Under Warrants (in shares)	25
Warrant Six [Member]
Expiration Date	May 11, 2021
Exercise Price (in dollars per share) | $ / shares	$ 7,740
Shares Outstanding Under Warrants (in shares)	6
Warrant Seven [Member]
Expiration Date	Jun. 20, 2026
Exercise Price (in dollars per share) | $ / shares	$ 4,980
Shares Outstanding Under Warrants (in shares)	101
Warrant Eight [Member]
Expiration Date	May 25, 2027
Exercise Price (in dollars per share) | $ / shares	$ 9,500
Shares Outstanding Under Warrants (in shares)	223
Warrant Nine [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share) | $ / shares	$ 3.40
Shares Outstanding Under Warrants (in shares)	285,632
Warrant Ten [Member]
Expiration Date	Nov. 26, 2024
Exercise Price (in dollars per share) | $ / shares	$ 18.36
Shares Outstanding Under Warrants (in shares)	989,379
Warrant Eleven [Member]
Expiration Date	Apr. 21, 2025
Exercise Price (in dollars per share) | $ / shares	$ 3.40
Shares Outstanding Under Warrants (in shares)	413,210
Warrant Twelve [Member]
Expiration Date	Jan. 19, 2026
Exercise Price (in dollars per share) | $ / shares	$ 3.40
Shares Outstanding Under Warrants (in shares)	8,104,880

Note 11 - Common Stock - Assump

Note 11 - Common Stock - Assumptions (Details) - Warrant [Member]	Jan. 19, 2021	Jan. 18, 2021
Measurement Input, Exercise Price [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.4	6.37
Measurement Input, Exercise Price [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.4	6.1
Measurement Input, Share Price [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.19	3.19
Measurement Input, Share Price [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.19	3.19
Measurement Input, Expected Term [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	4.3	4.3
Measurement Input, Expected Term [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	3.9	3.9
Measurement Input, Price Volatility [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.9	0.9
Measurement Input, Price Volatility [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.9	0.9
Measurement Input, Risk Free Interest Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.0033	0.0033
Measurement Input, Risk Free Interest Rate [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0.0033	0.0033
Measurement Input, Expected Dividend Rate [Member] | Series A-2 and Series B-2 Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0	0
Measurement Input, Expected Dividend Rate [Member] | Series B Warrants [Member]
Warrants and Rights Outstanding, Measurement Input	0	0

Note 12 - Summary of Stock Op_3

Note 12 - Summary of Stock Options (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Jan. 31, 2021	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		981,551		986,399
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)		$ 18.42		$ 19.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)		8 years 292 days		8 years 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		7,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%	0.00%
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 2,011,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		1 year 292 days
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total		$ 4,186,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 109 days
The 2006 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		12
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)		$ 9,920
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)		1 year 292 days
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		981,539
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)		91,755
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price, Ending Balance (in dollars per share)		$ 18.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)		8 years 292 days
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)	307,705
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	1,758,951			1,451,246
The 2013 Plan [Member] | Employees and Nonemployees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		7,000	46,800
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 2.19	$ 8.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		0			0
The 2013 Plan [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)		687,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period (in shares)		3,000
The 2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Employees and Board Members [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		690,000
The 2013 Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number, Ending Balance (in shares)		232
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		0	0
2017 Employee Stock Purchase Plan [Member]
Employee Stock Ownership Plan (ESOP), Number of Suspense Shares (in shares)		22

Note 12 - Summary of Stock Op_4

Note 12 - Summary of Stock Options - Summary of Option Activity Under All Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Options outstanding, beginning of period (in shares)	986,399
Options outstanding, beginning of period, weighted average exercise price (in dollars per share)	$ 19.10
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)	8 years 292 days	8 years 328 days
Options outstanding, aggregate intrinsic value		$ 675
Options granted (in shares)	7,000
Options granted, weighted average exercise price (in dollars per share)	$ 3.25
Options exercised (in shares)
Options exercised, weighted average exercise price (in dollars per share)
Options canceled (in shares)	(11,848)
Options canceled, weighted average exercise price (in dollars per share)	$ 66.81
Options outstanding, end of period (in shares)	981,551	986,399
Options outstanding, end of period, weighted average exercise price (in dollars per share)	$ 18.42	$ 19.10
Vested and exercisable and expected to vest, end of period (in shares)	928,262
Vested and exercisable and expected to vest, end of period, weighted average exercise price (in dollars per share)	$ 18.96
Vested and exercisable and expected to vest, end of period, weighted average remaining contractual term (Year)	8 years 292 days
Vested and exercisable and expected to vest, end of period, aggregate intrinsic value
Vested and exercisable, end of period (in shares)	294,253
Vested and exercisable, end of period, weighted average exercise price (in dollars per share)	$ 38.04
Vested and exercisable, end of period, weighted average remaining contractual term (Year)	8 years 219 days
Vested and exercisable, end of period, aggregate intrinsic value

Note 12 - Summary of Stock Op_5

Note 12 - Summary of Stock Options - Summary of Options Outstanding and Exercisable (Details)	3 Months Ended
	Mar. 31, 2021$ / sharesshares
Options outstanding, number (in shares) | shares	981,551
Options outstanding, weighted average exercise price (in dollars per share)	$ 18.42
Options outstanding, weighted average remaining contractual term (Year)	8 years 292 days
Options exercisable, number exercisable (in shares) | shares	294,253
Options exercisable, weighted average exercise price (in dollars per share)	$ 38.04
Range One [Member]
Exercise price range, lower limit (in dollars per share)	3.06
Exercise price range, upper limit (in dollars per share)	$ 8.91
Options outstanding, number (in shares) | shares	962,600
Options outstanding, weighted average exercise price (in dollars per share)	$ 8.28
Options outstanding, weighted average remaining contractual term (Year)	8 years 292 days
Options exercisable, number exercisable (in shares) | shares	284,952
Options exercisable, weighted average exercise price (in dollars per share)	$ 8.67
Range Two [Member]
Exercise price range, lower limit (in dollars per share)	10.90
Exercise price range, upper limit (in dollars per share)	$ 13.60
Options outstanding, number (in shares) | shares	15,500
Options outstanding, weighted average exercise price (in dollars per share)	$ 12.64
Options outstanding, weighted average remaining contractual term (Year)	8 years 328 days
Options exercisable, number exercisable (in shares) | shares	6,490
Options exercisable, weighted average exercise price (in dollars per share)	$ 12.98
Range Three [Member]
Exercise price range, lower limit (in dollars per share)	380
Exercise price range, upper limit (in dollars per share)	$ 580
Options outstanding, number (in shares) | shares	125
Options outstanding, weighted average exercise price (in dollars per share)	$ 552
Options outstanding, weighted average remaining contractual term (Year)	8 years 73 days
Options exercisable, number exercisable (in shares) | shares	116
Options exercisable, weighted average exercise price (in dollars per share)	$ 563.62
Range Four [Member]
Exercise price range, lower limit (in dollars per share)	1,000
Exercise price range, upper limit (in dollars per share)	$ 1,970
Options outstanding, number (in shares) | shares	1,888
Options outstanding, weighted average exercise price (in dollars per share)	$ 1,432.98
Options outstanding, weighted average remaining contractual term (Year)	7 years 219 days
Options exercisable, number exercisable (in shares) | shares	1,395
Options exercisable, weighted average exercise price (in dollars per share)	$ 1,438.84
Range Five [Member]
Exercise price range, lower limit (in dollars per share)	2,020
Exercise price range, upper limit (in dollars per share)	$ 2,830
Options outstanding, number (in shares) | shares	71
Options outstanding, weighted average exercise price (in dollars per share)	$ 2,521.55
Options outstanding, weighted average remaining contractual term (Year)	6 years 73 days
Options exercisable, number exercisable (in shares) | shares	55
Options exercisable, weighted average exercise price (in dollars per share)	$ 2,528.73
Range Six [Member]
Exercise price range, lower limit (in dollars per share)	3,110
Exercise price range, upper limit (in dollars per share)	$ 3,580
Options outstanding, number (in shares) | shares	189
Options outstanding, weighted average exercise price (in dollars per share)	$ 3,439.26
Options outstanding, weighted average remaining contractual term (Year)	7 years 146 days
Options exercisable, number exercisable (in shares) | shares	157
Options exercisable, weighted average exercise price (in dollars per share)	$ 3,453.69
Range Seven [Member]
Exercise price range, lower limit (in dollars per share)	4,360
Exercise price range, upper limit (in dollars per share)	$ 4,970
Options outstanding, number (in shares) | shares	595
Options outstanding, weighted average exercise price (in dollars per share)	$ 4,552.59
Options outstanding, weighted average remaining contractual term (Year)	6 years 73 days
Options exercisable, number exercisable (in shares) | shares	517
Options exercisable, weighted average exercise price (in dollars per share)	$ 4,555.78
Range Eight [Member]
Exercise price range, lower limit (in dollars per share)	5,010
Exercise price range, upper limit (in dollars per share)	$ 5,670
Options outstanding, number (in shares) | shares	294
Options outstanding, weighted average exercise price (in dollars per share)	$ 5,373.27
Options outstanding, weighted average remaining contractual term (Year)	6 years 36 days
Options exercisable, number exercisable (in shares) | shares	284
Options exercisable, weighted average exercise price (in dollars per share)	$ 5,365.88
Range Nine [Member]
Exercise price range, lower limit (in dollars per share)	6,000
Exercise price range, upper limit (in dollars per share)	$ 6,000
Options outstanding, number (in shares) | shares	138
Options outstanding, weighted average exercise price (in dollars per share)	$ 6,000
Options outstanding, weighted average remaining contractual term (Year)	4 years 255 days
Options exercisable, number exercisable (in shares) | shares	138
Options exercisable, weighted average exercise price (in dollars per share)	$ 6,000
Range Ten [Member]
Exercise price range, lower limit (in dollars per share)	7,140
Exercise price range, upper limit (in dollars per share)	$ 7,920
Options outstanding, number (in shares) | shares	139
Options outstanding, weighted average exercise price (in dollars per share)	$ 7,722.73
Options outstanding, weighted average remaining contractual term (Year)	5 years 219 days
Options exercisable, number exercisable (in shares) | shares	137
Options exercisable, weighted average exercise price (in dollars per share)	$ 7,720.15
Range Eleven [Member]
Exercise price range, lower limit (in dollars per share)	9,920
Exercise price range, upper limit (in dollars per share)	$ 9,920
Options outstanding, number (in shares) | shares	12
Options outstanding, weighted average exercise price (in dollars per share)	$ 9,920
Options outstanding, weighted average remaining contractual term (Year)	1 year 292 days
Options exercisable, number exercisable (in shares) | shares	12
Options exercisable, weighted average exercise price (in dollars per share)	$ 9,920

Note 12 - Summary of Stock Op_6

Note 12 - Summary of Stock Options - Valuation Assumptions for Stock Options (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Expected term (Year)	5 years	5 years
Average volatility	87.00%	73.00%
Risk-free interest rate	0.82%	0.45%
Dividend yield	0.00%	0.00%

Note 12 - Summary of Stock Op_7

Note 12 - Summary of Stock Options - Stock-based Compensation Expense Included in the Statement of Income (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Stock-based compensation expense	$ 810	$ 710
Cost of Sales [Member]
Stock-based compensation expense	55	60
Research and Development Expense [Member]
Stock-based compensation expense	97	86
Selling, General and Administrative Expenses [Member]
Stock-based compensation expense	$ 658	$ 564

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) xbrli-pure in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Income Tax Expense (Benefit), Total	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%	0.00%

Note 14 - Related Party Trans_2

Note 14 - Related Party Transactions (Details Textual) - Stellartech Research Corporation [Member] - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Stock Issued During Period, Shares, New Issues (in shares)	38
Related Party Transaction, Amounts of Transaction	$ 77,000	$ 282,000
Due to Related Parties, Total	$ 1,000		$ 9,000

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	May 13, 2021	Mar. 31, 2021	Mar. 31, 2020	Jan. 19, 2021	Jan. 18, 2021	Apr. 20, 2020
Proceeds from Issuance of Common Stock		$ 25,122,000
Series A-2 and Series B-2 Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 3.40	$ 6.371	$ 6.371
Subsequent Event [Member] | Purchase Agreement with LPC [Member]
Stock Issued During Period, Shares, New Issues (in shares)	250,000
Shares Issued, Price Per Share (in dollars per share)	$ 2.817
Proceeds from Issuance of Common Stock	$ 704,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 2.817